Search Result

Results for "

androgen receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (203) 5 alpha Reductase (5) Adrenergic Receptor (1) Akt (1) Aldose Reductase (1) Apoptosis (22) Aryl Hydrocarbon Receptor (2) Autophagy (18) Bacterial (2) Bcl-2 Family (1) Calcium Channel (2) Cannabinoid Receptor (1) Caspase (1) CDK (1) CXCR (1) Cytochrome P450 (5) Drug Metabolite (6) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (4) Epigenetic Reader Domain (3) Estrogen Receptor/ERR (8) Fatty Acid Synthase (FASN) (1) Fungal (8) Glucocorticoid Receptor (7) Histone Acetyltransferase (4) HIV (4) HSP (1) HSV (1) Isotope-Labeled Compounds (16) Keap1-Nrf2 (1) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (6) MDM-2/p53 (1) Mineralocorticoid Receptor (10) Mitophagy (1) MNK (1) Molecular Glues (2) NF-κB (1) NO Synthase (1) p38 MAPK (1) Parasite (6) PARP (1) Phosphatase (2) PPAR (2) Progesterone Receptor (12) Prostaglandin Receptor (1) PROTAC Linkers (2) PROTACs (22) SNIPERs (2) Thyroid Hormone Receptor (1) Toll-like Receptor (TLR) (2) Topoisomerase (1)
By Research Areas:	Cancer (192) Cardiovascular Disease (8) Endocrinology (60) Infection (14) Inflammation/Immunology (10) Metabolic Disease (14) Neurological Disease (3)
Oligonucleotides:	Cholesterol (1)

251

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Androgen Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155478

Androgen receptor-IN-6	Androgen Receptor	Cancer
Androgen receptor-IN-6 (compound 16) is an orally available androgen receptor (Androgen Receptor) potent inhibitor (IC₅₀=0.12 μM in vitro), targeting the disordered N-terminal domain (NTD). Androgen receptor-IN-6 has good Caco2 cell membrane permeability and has an oral activity (F/%) of 16% in male CD-1 mice .

HY-112689

Androgen receptor antagonist 9	Androgen Receptor	Endocrinology
Androgen receptor antagonist 9 (compound 28) is an antagonist of the androgen receptor .

HY-W248665A

Androgen receptor degrader-1	Androgen Receptor	Cancer
Androgen receptor degrader-1 (compound 18) is a potent **androgen receptor** degrader. Androgen receptor degrader-1 can be used in research of cancer .

HY-W584986

Androgen receptor degrader-2	Androgen Receptor	Cancer
Androgen receptor degrader-2 (compound 9) is a potent **androgen receptor** degrader. Androgen receptor degrader-2 can be used in research of cancer .

HY-131953

Androgen receptor-IN-3	Androgen Receptor	Cancer
Androgen receptor-IN-3 (Compound 22) is an **androgen receptor** inhibitor. Androgen receptor-IN-3 inhibits AR-driven transcriptional activity in LNCaP cells, with an IC₅₀ of 5.04 μM .

HY-151220

Androgen receptor-IN-4	Androgen Receptor	Others
Androgen receptor-IN-4 (Compound 206) is an **androgen receptor** inhibitor, and can be used for research of Kennedy's disease .

HY-153276

Androgen receptor-IN-5	Androgen Receptor	Cancer
Androgen receptor-IN-5 is an **androgen receptor** inhibitor with potent anticancer effects. Androgen receptor-IN-5 also inhibits the production of IL-17A, IL- 17F and INF-γ (WO2023281097A1,Example 1/1) .

HY-162764

Androgen receptor degrader-5	Androgen Receptor	Cancer
Androgen receptor degrader-5 (compound 14k) exhibits promising properties, including superior **androgen receptor** degradation activity and antiproliferative activity .

HY-153772

Androgen receptor antagonist 8	Androgen Receptor	Cancer
Androgen receptor antagonist 8 (Example 13) is an **androgen receptor** antagonist. Androgen receptor antagonist 8 inhibits prostate specific antigen secretion in LNcap cell (IC₅₀: 88 nM). Androgen receptor antagonist 8 can be used for prostate cancer research .

HY-160659

Androgen receptor antagonist 10	Androgen Receptor	Endocrinology
Androgen receptor antagonist 10 (compound 6h) is a **androgen receptor** antagonist. Androgen receptor antagonist 10 reduces the wax esters in the golden syrian hamster model .

HY-146026

Androgen receptor antagonist 3	Androgen Receptor	Cancer
Androgen receptor antagonist 3 (Compound C18) is an androgen receptor (AR) antagonist with an IC₅₀ of 2.4 μM. Androgen receptor antagonist 3 shows anticancer activities .

HY-136582

Masofaniten androgen receptor-IN-2	Androgen Receptor	Cancer
Masofaniten (Androgen receptor-IN-2) is a potent and orally active **androgen receptor** inhibitor. Masofaniten has antitumor activity against prostate cancer .

HY-169349

Androgen receptor antagonist 12	Androgen Receptor	Cancer
Androgen receptor antagonist 12 (Compound EF2) is an orally active **Androgen receptor** (AR) antagonist (IC₅₀: 0.30 μM). Androgen receptor antagonist 12 inhibits transcriptional activity of variant AR mutants and and the proliferation of AR-positive PCa cell lines. Androgen receptor antagonist 12 blocks AR nuclear translocation. Androgen receptor antagonist 12 inhibits tumor growth in a C4-2B xenograft mouse model. Androgen receptor antagonist 12 can be used for prostate cancer (PCa) research .

HY-146027

Androgen receptor antagonist 4	Androgen Receptor	Cancer
Androgen receptor antagonist 4 (Compound AT2) is an androgen receptor (AR) antagonist with an IC₅₀ of 0.15 μM. Androgen receptor antagonist 4 efficiently antagonizes AR transcriptional activity, suppresses downstream target gene of AR, and blocks the DHT-induced AR nuclear translocation. Androgen receptor antagonist 4 shows anticancer activities .

HY-146494

Androgen receptor antagonist 5	Androgen Receptor	Cancer
Androgen receptor antagonist 5 (compound 42f) is a potent androgen receptor (AR) antagonist with an IC₅₀ value of 6.17 μM. Androgen receptor antagonist 5 can effectively impair AR nuclear translocation, reducing the levels of nuclear AR, and disrupts AR-mediated gene regulation. Androgen receptor antagonist 5 has antiproliferative activity against LNCaP and exhibits antitumor activity in LNCaP xenograft tumor mice model. Androgen receptor antagonist 5 can be used for researching prostate cancer .

HY-152524

Androgen receptor antagonist 7	Androgen Receptor	Cancer
Androgen receptor antagonist 7 is an effective **androgen receptor (AR) antagonist with an IC₅₀** value of 1.18 µM. Androgen receptor antagonist 7 has biological activity in vitro and inhibits the expression of AR target in a time and dose dependent manner with an GI₅₀ value of 7.9 µM .

HY-130992

Androgen receptor antagonist 1	Androgen Receptor Ligands for Target Protein for PROTAC	Cancer
Androgen receptor antagonist 1 is an orally available full **androgen receptor (AR) antagonist with an IC₅₀** of 59 nM . Androgen receptor antagonist 1 (Compound 6) can be used in the synthesis of PROTAC AR degraders, which results 24% and 47 % AR protein degradation in LNCaP cells at 1 μM and 10 μM, respectively .

HY-121094

Androgen receptor allosteric antagonist 1	Estrogen Receptor/ERR	Cancer
Androgen receptor allosteric antagonist 1(compound D36)is a a llosteric, competitive androgen receptor (AR) antagonist with the K_i of 9 μM. Androgen receptor allosteric antagonist 1 inhibits R1881-mediated transcription and proliferation and can be used for study of prostate cancer .

HY-168141

Androgen receptor antagonist 11	Others	Cancer

HY-103246

TFM-4AS-1	Androgen Receptor	Cancer
TFM-4AS-1 is a *selective androgen* receptor modulator (SARM)*, and a potent androgen* receptor (AR) ligand with an IC₅₀ of 38 nM. TFM-4AS-1 is a gene-selective agonist .

HY-103577

LG-121071	Androgen Receptor	Cancer
LG-121071 is an orally active and selective **androgen receptor modulator with a K_i** of 17 nM .

HY-111044

(+)-JNJ-37654032	Androgen Receptor	Cancer
(+)-JNJ-37654032 is an orally active and selective **androgen receptor** modulator. (+)-JNJ-37654032 can be used in the study of muscle-wasting diseases .

HY-122025

AC-262536 1 Publications Verification	Androgen Receptor	Metabolic Disease
AC-262536 is a selective and non-steroidal **androgen receptor modulators (SARMs*) with beneficial anabolic effects. AC-262536 exhibits potent agonist activity at the androgen* receptor, with an affinity in the low nanomolar range (1-10 nM) .

HY-139436

ARD-2585	PROTACs Androgen Receptor	Cancer
ARD-2585 is an exceptionally potent and orally active PROTAC degrader of **androgen receptor** .

HY-160221

PROTAC AR Degrader-7	Androgen Receptor	Cancer
PROTAC AR Degrader-7 (compound 99) is a select **androgen receptor degrader with an IC₅₀** value of 3 nM. PROTAC AR Degrader-7 inhibits the proliferation of prostate cancer cells .

HY-156751

PROTAC AR Degrader-6	PROTACs Androgen Receptor	Cancer
PROTAC AR Degrader-6 (Compound 1) is a PROTAC **androgen receptor** degrader (DC₅₀: 10 nM in VCaP cell). PROTAC AR Degrader-6 blocks the process of androgen receptor transduction and also degrades the receptor itself. PROTAC AR Degrader-6 can be used for prostate cancer research. Pink: AR ligand (HY-130845); Blue: E3 ligase ligand (HY-W1003189); Black: linker (HY-169975) .

HY-118409

VPC-3033	Androgen Receptor	Endocrinology Cancer
VPC-3033 is an **androgen receptor** antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC₅₀: 0.625-2.5 μM), can effectively inhibit androgen receptor transcriptional activity (IC₅₀=0.3 μM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide (HY-70002) .

HY-157455

AR antagonist 5	Androgen Receptor	Cancer
AR antagonist 5 (compound 30a) is a selective androgen receptor (AR) antagonist with an IC₅₀ value of 134.8 nM. AR antagonist 5 has favorable pharmacokinetic properties and shows a high skin exposure and low plasma exposure ^[1.

HY-103578

S-40503	Androgen Receptor	Cancer
S-40503 is an orally active and selective **androgen receptor** modulator. S-40503 significantly increases the bone mineral density (BMD) and biomechanical strength of femoral cortical bone .

HY-164807

SARD279	Androgen Receptor	Cancer
SARD279 is a potent and selective **Androgen Receptor degrader with DC₅₀** value of 1099 nM. SARD279 can be used in prostate cancer research .

HY-W653723

N-Nitrosodicyclohexylamine NDCHA	Androgen Receptor	Endocrinology
N-Nitrosodicyclohexylamine (NDCHA) is a N-nitrosocompound with anti-androgenic activities. N-Nitrosodicyclohexylamine shows the competitive binding to androgen receptor (AR) against 5α-dihydrotestosterone and decreased the level of AR protein .

HY-131388

ABM-14	Ligands for Target Protein for PROTAC	Cancer
ABM-14 is a ligand for targeting androgen receptor (AR) for PROTAC. ABM-14 binds to a ligand for VHL via linker to form ARCC-4 (HY-130492) to degrade AR .

HY-13607

BMS-641988	Androgen Receptor	Cancer
BMS-641988 (compound 23) is an oral active nonsteroidal **androgen receptor antagonist with the K_i** of 1.7 nM. BMS-641988 shows anticancer activity .

HY-70002B

Enzalutamide carboxylic acid 1 Publications Verification MDV3100 carboxylic acid	Drug Metabolite	Cancer
Enzalutamide carboxylic acid (MDV3100 carboxylic acid) is an inactive metabolite of Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist .

HY-123310

JNJ-26146900	Androgen Receptor	Cancer
JNJ-26146900 is a potent and orally active **androgen receptor antagonist with a K_i** value of 400nM for rat AR. JNJ-26146900 is a nonsteroidal androgen receptor (AR) ligand. JNJ-26146900 reduces prostate tumor size and prevents bone loss. JNJ-26146900 can be used in research of cancer .

HY-160020

ET516	Androgen Receptor	Cancer
ET516 is a potent inhibitor of **Androgen Receptor**. ET516 significantly inhibits the proliferation and tumor growth of prostate cancer cells expressing AR-resistant mutants .

HY-W653723R

N-Nitrosodicyclohexylamine (Standard)	Androgen Receptor	Endocrinology
N-Nitrosodicyclohexylamine (Standard) is the analytical standard of N-Nitrosodicyclohexylamine. This product is intended for research and analytical applications. N-Nitrosodicyclohexylamine (NDCHA) is a N-nitrosocompound with anti-androgenic activities. N-Nitrosodicyclohexylamine shows the competitive binding to androgen receptor (AR) against 5α-dihydrotestosterone and decreased the level of AR protein .

HY-14249

Bicalutamide 10+ Cited Publications	Androgen Receptor Autophagy	Cancer
Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .

HY-138641

Bavdegalutamide 3 Publications Verification ARV-110	PROTACs Androgen Receptor	Cancer
Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer .

HY-157491

K2-B4-5e	PROTACs Androgen Receptor Epigenetic Reader Domain	Cancer
K2-B4-5e is a E3 ligase KLHDC2-based BRD4 and androgen receptor (AR) degradation PROTAC. K2-B4-5e is capable of inducing rapid and robust degradation of BET-family and AR proteins in cells .

HY-108250

(R)-Bicalutamide	Androgen Receptor	Cancer
(R)-Bicalutamide is the (R)-enantiomer of Bicalutamide (HY-14249). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer .

HY-14249R

Bicalutamide (Standard)	Androgen Receptor Autophagy	Cancer
Bicalutamide (Standard) is the analytical standard of Bicalutamide. This product is intended for research and analytical applications. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .

HY-14249S1

Bicalutamide-d5	Androgen Receptor Autophagy Isotope-Labeled Compounds	Cancer
Bicalutamide-d₅ is deuterated labeled Bicalutamide (HY-14249). Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .

HY-133045

VHL Ligand 8	Ligands for E3 Ligase	Cancer
VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM .

HY-145709

Ar-V7-IN-1	Androgen Receptor	Cancer
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications, in particular cancers such as prostate cancer (extracted from patent WO2018114781A1, compound 43) .

HY-156111

ARD-1676	PROTACs Androgen Receptor	Cancer
ARD-1676 is an orally available androgen receptor (AR) PROTAC degrader, consisting of AR ligand and cereblon ligand. ARD-1676 has AR-degrading activity in vitro and in vivo and inhibits VCaP tumor growth in mouse xenograft tumor models .

HY-153342

Luxdegalutamide ARV-766	PROTACs Androgen Receptor	Cancer
Luxdegalutamide (ARV-766) is an orally active protein hydrolysis targeted chimeric (PROTAC) targeting androgen receptor (AR), which can degrade AR resistance related mutants, including T878/H875/L702 mutants. Luxdegalutamide has anti-tumor activity and can be used in the study of castration resistant prostate cancer .

HY-120018

VPC-13566	Androgen Receptor	Cancer
VPC-13566, a BF3-specific small molecule, is an androgen receptor (AR) inhibitor. VPC-13566 is effective in inhibiting AR transcriptional activity in vitro as well as the growth of AR-dependent PCa cell lines. VPC-13566 can be used as a chemical probe to help identify unknown AR partners.VPC-13566 can be used for the research of cancer.

HY-149862

ARD-2051	PROTACs Androgen Receptor	Cancer
ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC₅₀ values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer .

HY-164373

SC428	Androgen Receptor Apoptosis	Cancer
SC428 is an androgen receptor (AR) inhibitor that targets the N-terminal domain. SC428 potently decrease the transactivation of (AR)-V7, (AR)v567es, as well as full-length ( AR ) (AR-FL) and its LBD mutants, substantially. SC428 inhibits androgen-stimulated (AR)-FL nuclear translocation, chromatin binding, and (AR) -regulated gene transcription. SC428 inhibits the proliferation of tumor cells in vitro. SC428 inhibits tumor cell growth by inducing apoptosis in mice transplanted with 22RV1 .

Cat. No.	Product Name

HY-L126

Nuclear Receptor Compound Library

669 compounds

Nuclear receptors (NR) are proteins found in cells that sense androgen and thyroid hormones and certain other molecules. They are ligand-activated transcription factors that participate in many aspects of human physiology and pathology, and regulate the expression of various important genes.

Nuclear receptors have become one of the main targets in the development of new drug strategies, providing a unique type of receptors for studying a variety of human diseases, such as breast cancers, skin disorders and diabetes. 13% of U.S. Food and Drug Administration (FDA) approved drugs target nuclear receptors.

MCE supplies a unique collection of 669 nuclear receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on nuclear receptor. MCE Nuclear Receptor Library is a useful tool for drugs research related to cancer, skin disease and diabetes.

Cat. No.	Product Name	Target	Research Area

HY-P2413

Ac-PPPHPHARIK-NH2	Peptides	Others
Ac-PPPHPHARIK-NH2 (compound S1) is a compound that inhibits the interaction between androgen receptor and Src. It can inhibit the binding of androgen or estrogen-induced receptor and Src in cancer cells, as well as the activation of related signaling pathways, and can also inhibit cell cycle progression and tumor growth.

HY-P2446

ORG 30276 APTAA-LHRH	Peptides	Endocrinology
ORG 30276 (APTAA-LHRH) is a potent GnRH antagonist that effectively reduces serum LH and FSH levels in male rats. ORG 30276 significantly decreases unoccupied pituitary GnRH receptors, leading to suppressed gonadotropin secretion. ORG 30276 treatment results in a considerable reduction in mRNA levels of gonadotropin beta-subunits in the pituitary gland. ORG 30276's effects on gonadotropin dynamics can be selectively reversed by the replacement of specific sex steroids, with androgens being particularly effective for the FSH beta-subunit mRNA levels.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15758

3,3'-Diindolylmethane 5+ Cited Publications DIM; Arundine; HB 236	Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Disease Research Fields Alkaloid Dimers Cancer	Androgen Receptor Autophagy
3,3'-Diindolylmethane is a strong, pure **androgen receptor** (AR) antagonist.

HY-N9917

Galloylalbiflorin 6′-O-Galloylalbiflorin	Paeonia lactiflora Pall. Source classification Polyphenols Plants Paeoniaceae	Androgen Receptor
Galloylalbiflorin (6′-O-Galloylalbiflorin) is an **androgen receptor (AR) antagonist (IC₅₀*=53.3 μM) and can be found in the roots of Paeonia lactiflora. Galloylalbiflorin shows anti-androgens* activity .

HY-B0469

Medroxyprogesterone acetate 15+ Cited Publications Medroxyprogesterone 17-acetate; Farlutin	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Progesterone Receptor Androgen Receptor Glucocorticoid Receptor Endogenous Metabolite
Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, *androgen* and glucocorticoid receptors .

HY-110028

Leelamine hydrochloride	Structural Classification other families Classification of Application Fields Pinaceae Terpenoids Source classification Diterpenoids Plants Disease Research Fields Pinus massoniana Lamb. Endocrinology	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees . Leelamine hydrochloride is a *cannabinoid receptor* type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis** in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of **androgen receptor**, which is known to regulate fatty acid synthesis ^[2,3].

HY-14650

DHEA Maximum Cited Publications 26 Publications Verification Prasterone; Dehydroisoandrosterone; Dehydroepiandrosterone	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Androgen Receptor Endogenous Metabolite
DHEA (Prasterone) is one of the most abundant steroid hormones. DHEA (Prasterone) mediates its action via multiple signaling pathways involving specific membrane receptors and via transformation into androgen and estrogen derivatives (e.g., androgens, estrogens, 7α and 7β DHEA, and 7α and 7β epiandrosterone derivatives) acting through their specific receptors.

HY-15194

Dimethylcurcumin 10+ Cited Publications ASC-J9; GO-Y025	Zingiber officinale Roscoe Structural Classification Classification of Application Fields Simple Phenylpropanols Source classification Phenylpropanoids Plants Disease Research Fields Zingiberaceae Cancer	Androgen Receptor
Dimethylcurcumin (ASC-J9) is an **androgen receptor** degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.

HY-N0790

Lupeol 3 Publications Verification Clerodol; Monogynol B; Fagarasterol	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Cancer	Androgen Receptor Apoptosis
Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .

HY-N3755

Dihydroresveratrol	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Source classification Phenols Polyphenols Plants Endogenous metabolite Disease Research Fields Dioscorea bulbifera Linn. Dioscoreaceae Cancer	Estrogen Receptor/ERR
Dihydroresveratrol, a potent phytoestrogen, is a hormone receptor modulator. Dihydroresveratrol exhibits proliferative effects in androgen-independent prostate and breast cancer cells at picomolar and nanomolar concentrations .

HY-N6714

Alternariol	Infection Structural Classification Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Disease Research Fields	Topoisomerase Androgen Receptor Estrogen Receptor/ERR Apoptosis
Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen *Receptor) effects. Alternariol can induce apoptosis*, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects .

HY-127057

Lambertianic acid	Pinus lambertiana Douglas Structural Classification Pinaceae Terpenoids Source classification Diterpenoids Plants	Androgen Receptor CDK MDM-2/p53 Apoptosis Caspase PARP Bcl-2 Family
Lambertianic acid is a bioactive diterpene with anti-allergic, antibacterial and anticancer activities. Lambertianic acid decreases **androgen receptor protein levels, cellular and secretory levels of prostate-specific antigen. Lambertianic acid also suppresses cell proliferation by inducing G1 arrest, downregulating CDK4/6 and cyclin D1, activating p53, p21 and p27. Lambertianic acid induces Apoptosis** and the expression of related proteins, including cleaved caspase-3/9, c-PARP and BAX, and inhibited BCl-2. Lambertianic acid is promising for research of prostate cancer .

HY-B0469R

Medroxyprogesterone acetate (Standard) 15+ Cited Publications Medroxyprogesterone 17-acetate(Standard); Farlutin (Standard)	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Progesterone Receptor Androgen Receptor Glucocorticoid Receptor Endogenous Metabolite
Medroxyprogesterone acetate (Standard) is the analytical standard of Medroxyprogesterone acetate. This product is intended for research and analytical applications. Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, *androgen* and glucocorticoid receptors .

HY-N2345

Procyanidin B3	Structural Classification Classification of Application Fields Source classification Plants Flavonoids other families Functional Molecules Research of Health Products Phenols Polyphenols Biflavones Disease Research Fields Cancer	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen *receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2* complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-N0790R

Lupeol (Standard)	Triterpenes Structural Classification other families Terpenoids Source classification Plants	Androgen Receptor Apoptosis
Lupeol (Standard) is the analytical standard of Lupeol. This product is intended for research and analytical applications. Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic?triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent?androgen receptor (AR)?inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .

HY-15758R

3,3'-Diindolylmethane (Standard)	Alkaloids Structural Classification other families Source classification Plants Alkaloid Dimers	Androgen Receptor Autophagy
3,3'-Diindolylmethane (Standard) is the analytical standard of 3,3'-Diindolylmethane. This product is intended for research and analytical applications. 3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist.

HY-N7210

Kahweol acetate	Structural Classification Natural Products Source classification Rubiaceae Plants Coffea arabica L.	Apoptosis
Kahweol acetate, a bioactive compound found in coffee, has been identified for its potent anti-cancer properties, particularly in inhibiting the proliferation and migration of prostate cancer cells. Alongside cafestol, it shows dose-dependent effects in suppressing tumor growth and metastasis in both in vitro and in vivo studies. Mechanistically, kahweol acetate and cafestol induce apoptosis, inhibit epithelial-mesenchymal transition, and reduce androgen receptor activity, especially in androgen receptor-positive cells. They also downregulate chemokine receptors CCR2 and CCR5, crucial for cancer progression, without altering their ligand levels. These findings suggest that kahweol acetate, in combination with cafestol, may serve as promising therapeutic agents against prostate cancer .

HY-N7045

Isosilybin B 1 Publications Verification	Structural Classification Classification of Application Fields Source classification Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Flavanonols Flavonoids Glycine soya Phenols Polyphenols Disease Research Fields Cancer	Androgen Receptor Apoptosis
Isosilybin B, a flavonolignan isolated from Silybum marianum, has anti-prostate cancer (PCA) activity via inhibiting proliferation and inducing G1 phase arrest and apoptosis. Isosilybin B causes androgen receptor (AR) degradation .

HY-N2345R

Procyanidin B3 (Standard)	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Biflavones	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-N1943

Ailanthone Δ13-Dehydrochaparrinone	Structural Classification Simaroubaceae Ailanthus altissima (Mill.) Swingle Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Androgen Receptor
Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length androgen receptor (AR) (IC₅₀=69 nM) and constitutively active truncated AR splice variants (AR_1-651 IC₅₀=309 nM).

HY-N7043

Isosilybin A 2 Publications Verification	Structural Classification Classification of Application Fields Source classification Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Flavanonols Flavonoids Glycine soya Phenols Polyphenols Disease Research Fields Cancer	Apoptosis
Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting *Akt-NF-κB-androgen* receptor (AR)** axis .

HY-N2908

Atraric acid Methyl atrarate	Structural Classification Microorganisms Classification of Application Fields Phenols Essence, Fragrance Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	Androgen Receptor NO Synthase p38 MAPK NF-κB
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

HY-N7043R

Isosilybin A (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Apoptosis
Isosilybin A (Standard) is the analytical standard of Isosilybin A. This product is intended for research and analytical applications. Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis .

HY-113289

Brassicasterol	Infection Animals Classification of Application Fields Source classification Disease Research Fields Steroids Cancer	Akt Androgen Receptor Bacterial Drug Metabolite HSV
Brassicasterol is a metabolite of Ergosterol and has cardiovascular protective effects. Brassicasterol exerts anticancer effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol inhibits HSV-1 (IC₅₀=1.2 μM) and Mycobacterium tuberculosis. Brassicasterol also inhibits sterol δ 24-reductase, slowing the progression of atherosclerosis. Brassicasterol is also a cerebrospinal fluid biomarker for Alzheimer's disease .

Recombinant Proteins Recommended:

Androgen Receptor

Species:	Human (4)
Tag:	His (2) SUMO (1) Tag Free (1) GST (1)
Source:	Sf9 insect cells (1) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P71622

	WDR77 Protein, Human (His-SUMO) 2610312E17Rik; androgen receptor cofactor p44; C79984; HKMT1069; MEP 50; MEP-50; MEP50; Methylosome protein 50; WDR77	Human	E. coli
	WDR77 is a non-catalytic component of the methylosome complex with PRMT5 and CLNS1A and regulates arginine to dimethylarginine in spliceosomal Sm proteins and histones. This modification directs Sm proteins to SMN complexes, helping them assemble into small nuclear ribonucleoprotein core particles. WDR77 Protein, Human (His-SUMO) is the recombinant human-derived WDR77 protein, expressed by E. coli , with N-His, N-SUMO labeled tag. The total length of WDR77 Protein, Human (His-SUMO) is 312 a.a., with molecular weight of ~49.6 kDa.

HY-P701558

	RNF14 Protein, Human RNF14; E3 ubiquitin-protein ligase RNF14; androgen receptor-associated protein 54; HFB30; RING finger protein 14; Triad2 protein	Human	E. coli
	The RNF14 protein is a critical E3 ubiquitin protein ligase that leads to activation of the RNF14-RNF25 translation quality control pathway during ribosome stalling. RNF14 is recruited by GCN1 to ubiquitinate and degrade translation factors, mainly EEF1A1/eEF1A, as well as ETF1/eRF1 and ribosomal proteins (RPL0, RPL1, RPL12, RPS13, RPS17). RNF14 Protein, Human is the recombinant human-derived RNF14 protein, expressed by E. coli , with tag free. The total length of RNF14 Protein, Human is 473 a.a., .

HY-P701559

	RNF14 Protein, Human (His) RNF14; E3 ubiquitin-protein ligase RNF14; androgen receptor-associated protein 54; HFB30; RING finger protein 14; Triad2 protein	Human	E. coli
	The RNF14 protein is a critical E3 ubiquitin protein ligase that leads to activation of the RNF14-RNF25 translation quality control pathway during ribosome stalling. RNF14 is recruited by GCN1 to ubiquitinate and degrade translation factors, mainly EEF1A1/eEF1A, as well as ETF1/eRF1 and ribosomal proteins (RPL0, RPL1, RPL12, RPS13, RPS17). RNF14 Protein, Human (His) is the recombinant human-derived RNF14 protein, expressed by E. coli , with N-6*His labeled tag. The total length of RNF14 Protein, Human (His) is 473 a.a., .

HY-P701698

	HIPK3 Protein, Human (Sf9, GST) HIPK3; Homeodomain-interacting protein kinase 3; androgen receptor-interacting nuclear protein kinase; ANPK; Fas-interacting serine/threonine-protein kinase; FIST; Homolog of protein kinase YAK1	Human	Sf9 insect cells
	HIPK3 is a multifaceted serine/threonine protein kinase that plays multiple roles in transcriptional regulation, apoptosis, and steroidogenic gene expression. It phosphorylates the transcription factors JUN and RUNX2, contributing to complex gene expression control. HIPK3 Protein, Human (Sf9, GST) is the recombinant human-derived HIPK3 protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of HIPK3 Protein, Human (Sf9, GST) is 402 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0469S

Medroxyprogesterone acetate-d3
Medroxyprogesterone acetate-d₃ is deuterium labeled Medroxyprogesterone acetate. Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors[1].

HY-16060S

Apalutamide-d4
Apalutamide-d₄ is a deuterium labeled Apalutamide. Apalutamide is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[1].

HY-70002S1

Enzalutamide-d6
Enzalutamide-d₆ is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1].

HY-70002S

Deutenzalutamide
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells .

HY-135794S

11-Ketodihydrotestosterone-d3

11-Ketodihydrotestosterone-d₃ is the deuterium labeled 11-Ketodihydrotestosterone. 11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a Ki of 20.4 nM and an EC50 of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells[1][2].

HY-B0561S1

Spironolactone-d3
Spironolactone-d₃ is the deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes[1][2][3].

HY-14249S1

Bicalutamide-d5
Bicalutamide-d₅ is deuterated labeled Bicalutamide (HY-14249). Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .

HY-13604S

Cyproterone acetate-d3
Cyproterone acetate-d₃ is deuterium labeled Cyproterone acetate. Cyproterone acetate is an anti-androgen (IC50=7.1 nM) and progestogen synthetic steroid. Cyproterone acetate has affinity with progesteron and with glucocorticoidal receptors[1][2].

HY-14249S

Bicalutamide-d4
Bicalutamide-d₄ is the deuterium labeled Bicalutamide. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer[1].

HY-16060S3

Apalutamide-d7
Apalutamide-d₇ is deuterated labeled Apalutamide (HY-16060). Apalutamide (ARN-509) is a potent and competitive **androgen receptor (AR) antagonist, binding AR with an IC₅₀** of 16 nM .

HY-B0561S

Spironolactone-d7
Spironolactone-d₇ is the deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes[1][2][3].

HY-16060S1

Apalutamide-d3
Apalutamide-d₃ is the deuterium labeled Apalutamide[1]. Apalutamide (ARN-509) is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[2].

HY-B0561S2

Spironolactone-d3-1
Spironolactone-d₃-1 is deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes[1][2][3].

HY-16060S2

Apalutamide-13C,d3
Apalutamide- ¹³C,d₃ is the ¹³C- and deuterium labeled Apalutamide. Apalutamide (ARN-509) is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[1].

HY-111372S

Finerenone-d3

Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-13613S

Dutasteride-13C6
Dutasteride- ¹³C₆ is the ¹³C labeled Dutasteride[1]. Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT[2].

HY-B1986S

p,p'-DDE-d8
p,p'-DDE-d₈ is the deuterium labeled p,p'-DDE[1]. p,p'-DDE (4,4'-DDE), a major metabolite of persistent dichlorodiphenyltrichloroethane (DDT), is a potent androgen receptor antagonist, with an IC50 of 5 μM and a Ki of 3.5 μM[2].

HY-B0251S

Eplerenone-d3
Eplerenone-d₃ is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC50 of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch[1][2].

HY-13613S2

Dutasteride-13C,15N,d
Dutasteride- ¹³C, ¹⁵N,d is ¹⁵N and deuterated labeled Dutasteride (HY-13613). Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT .

HY-13676S

Megestrol acetate-d3

Megestrol acetate-d₃ is the deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway[1][2][3][4][5].

HY-13676S1

Megestrol acetate-d3-1

Megestrol acetate-d₃-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway[1][2][3][4][5].

HY-B0846S

Dimethomorph-d8
Dimethomorph-d₈ is the deuterium labeled Dimethomorph[1]. Dimethomorph is a fungicide belongs to the fungicide group of sterol biosynthesis inhibitor. Dimethomorph can inhibit fungal cell wall formation. Dimethomorph also inhibits androgen receptor (AR) activity in MDA-kb2 cells with an IC20 of 0.263 μM[2][3][4].

HY-106827S1

Trimegestone-13C,d3

Trimegestone- ¹³C,d₃ is ¹³C and deuterated labeled Trimegestone (HY-106827). Trimegestone (RU 27987) is an orally active 19-norpregnane progestin. Trimegestone binds to progesterone receptor (PR) with an IC₅₀ value of 3.3 nM (rat PR). Trimegestone increases alkaline phosphatase activity (EC₅₀=0.1 nM) but not luciferase activity. Trimegestone also shows a weak antiandrogenic activity (weak androgen receptor affinity). Trimegestone can be used in studies of contraception or menopausal syndromes .

HY-W754151

N-Desmethyl apalutamide-d4

N-Desmethyl apalutamide-d₄ is the deuterium-labeled N-Desmethyl-Apalutamide (HY-135331). N-Desmethyl Apalutamide is an active metabolite of Apalutamide. N-Desmethyl Apalutamide is a less potent antagonist of the androgen receptor and is responsible for one-third of the activity of Apalutamide. The formation of N-Desmethyl Apalutamide mediated predominantly by CYP2C8 and CYP3A4. N-Desmethyl Apalutamide is moderate to strong CYP3A4 and CYP2B6 inducer and has an excellent plasma-proteins bound concentration .

HY-116214S1

Cyprodinil-13C6

Cyprodinil- ¹³C₆ is the ¹³C₆ labeled Cyprodinil. Cyprodinil is an anilinopyrimidine broad-spectrum fungicide that inhibits the biosynthesis of methionine in phytopathogenic fungi. Cyprodinil inhibits mycelial cell growth of B. cinerea, P. herpotrichoides, and H. oryzae on amino acid-free media (IC₅₀s=0.44, 4.8, and 0.03 µM, respectively). Cyprodinil acts as an androgen receptor (AR) agonist (EC50=1.91 µM) in the absence of the AR agonist DHT and inhibits the androgenic effect of DHT (IC50=15.1 µM).

HY-135331S

N-Desmethyl-Apalutamide-15N,d4

N-Desmethyl-Apalutamide-15N,d4 is the ¹⁵N and deuterium labeled isotope of N-Desmethyl-Apalutamide (HY-135331). N-Desmethyl Apalutamide is an active metabolite of Apalutamide. N-Desmethyl Apalutamide is a less potent antagonist of the androgen receptor and is responsible for one-third of the activity of Apalutamide. The formation of N-Desmethyl Apalutamide mediated predominantly by CYP2C8 and CYP3A4. N-Desmethyl Apalutamide is moderate to strong CYP3A4 and CYP2B6 inducer and has an excellent plasma-proteins bound concentration .

HY-116214S

Cyprodinil-d5

Cyprodinil-d₅is the deuterium labeledCyprodinil(HY-116214) . Cyprodinil is an anilinopyrimidine broad-spectrum fungicide that inhibits the biosynthesis of methionine in phytopathogenic fungi. Cyprodinil inhibits mycelial cell growth of B. cinerea, P. herpotrichoides, and H. oryzae on amino acid-free media (IC₅₀s=0.44, 4.8, and 0.03 μM, respectively). Cyprodinil acts as an androgen receptor (AR) agonist (EC₅₀=1.91 μM) in the absence of the AR agonist DHT and inhibits the androgenic effect of DHT (IC₅₀=15.1 μM) .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80014

	Androgen receptor Antibody	WB, ICC/IF	Human
	Androgen receptor Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 99 kDa, targeting to Androgen receptor. It can be used for WB,ICC/IF assays with tag free, in the background of Human.

HY-P82076

	Ran Antibody (YA1821) RAN; ARA24; OK/SW-cl.81; GTP-binding nuclear protein Ran; androgen receptor-associated protein 24; GTPase Ran; Ras-like protein TC4; Ras-related nuclear protein	WB, ICC/IF, IP	Human, Mouse, Monkey
	Ran Antibody (YA1821) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1821), targeting Ran, with a predicted molecular weight of 24 kDa (observed band size: 24 kDa). Ran Antibody (YA1821) can be used for WB, ICC/IF, IP experiment in human, mouse, monkey background.

HY-P83471

	RNF14 Antibody (YA3216) RNF14; ARA54; HRIHFB2038; E3 ubiquitin-protein ligase RNF14; androgen receptor-associated protein 54; HFB30; RING finger protein 14; Triad2 protein	WB	Human, Mouse, Rat
	RNF14 Antibody (YA3216) is a biotin-conjugated non-conjugated IgG antibody, targeting RNF14, with a predicted molecular weight of 54 kDa (observed band size: 54 kDa). RNF14 Antibody (YA3216) can be used for WB experiment in human, mouse, rat background.

HY-P81998

	Pirh2 Antibody (YA1743) RCHY1; ARNIP; CHIMP; PIRH2; RNF199; ZNF363; RING finger and CHY zinc finger domain-containing protein 1; androgen receptor N-terminal-interacting protein; CH-rich-interacting match with PLAG1; E3 ubiquitin-protein ligase Pirh2; RING finger	WB	Human
	Pirh2 Antibody (YA1743) is a biotin-conjugated non-conjugated IgG antibody, targeting Pirh2, with a predicted molecular weight of 30 kDa (observed band size: 30 kDa). Pirh2 Antibody (YA1743) can be used for WB experiment in human background.